» Articles » PMID: 33109235

Epigenetic Crosstalk Between Hypoxia and Tumor Driven by HIF Regulation

Overview
Publisher Biomed Central
Specialty Oncology
Date 2020 Oct 28
PMID 33109235
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia is the major influence factor in physiological and pathological courses which are mainly mediated by hypoxia-inducible factors (HIFs) in response to low oxygen tensions within solid tumors. Under normoxia, HIF signaling pathway is inhibited due to HIF-α subunits degradation. However, in hypoxic conditions, HIF-α is activated and stabilized, and HIF target genes are successively activated, resulting in a series of tumour-specific activities. The activation of HIFs, including HIF-1α, HIF-2α and HIF-3α, subsequently induce downstream target genes which leads to series of responses, the resulting abnormal processes or metabolites in turn affect HIFs stability. Given its functions in tumors progression, HIFs have been regarded as therapeutic targets for improved treatment efficacy. Epigenetics refers to alterations in gene expression that are stable between cell divisions, and sometimes between generations, but do not involve changes in the underlying DNA sequence of the organism. And with the development of research, epigenetic regulation has been found to play an important role in the development of tumors, which providing accumulating basic or clinical evidences for tumor treatments. Here, given how little has been reported about the overall association between hypoxic tumors and epigenetics, we made a more systematic review from epigenetic perspective in hope of helping others better understand hypoxia or HIF pathway, and providing more established and potential therapeutic strategies in tumors to facilitate epigenetic studies of tumors.

Citing Articles

The epigenetic basis of hepatocellular carcinoma - mechanisms and potential directions for biomarkers and therapeutics.

Lin H, Jeon A, Chen K, Lee C, Wu L, Chong S Br J Cancer. 2025; .

PMID: 40057667 DOI: 10.1038/s41416-025-02969-8.


HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects.

Shi Y, Gilkes D Cell Mol Life Sci. 2025; 82(1):44.

PMID: 39825916 PMC: 11741981. DOI: 10.1007/s00018-024-05537-0.


PX-12 modulates vorinostat-induced acetylation and methylation marks in CAL 27 cells.

Akhlaq R, Ahmed T, Khan T, Yaseen Jeelani S, Joseph-Chowdhury J, Sidoli S Epigenomics. 2024; 17(2):79-87.

PMID: 39716806 PMC: 11792842. DOI: 10.1080/17501911.2024.2441652.


Progress in Lactate Metabolism and Its Regulation via Small Molecule Drugs.

Liu J, Zhou F, Tang Y, Li L, Li L Molecules. 2024; 29(23).

PMID: 39683818 PMC: 11643809. DOI: 10.3390/molecules29235656.


Targeting Tumor Hypoxia with Nanoparticle-Based Therapies: Challenges, Opportunities, and Clinical Implications.

Debnath S, Debnath M, Ghosh A, Srivastava R, Omri A Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39459028 PMC: 11510357. DOI: 10.3390/ph17101389.


References
1.
Zhou X, Chen J, Yi G, Deng M, Liu H, Liang M . Metformin suppresses hypoxia-induced stabilization of HIF-1α through reprogramming of oxygen metabolism in hepatocellular carcinoma. Oncotarget. 2015; 7(1):873-84. PMC: 4808039. DOI: 10.18632/oncotarget.6418. View

2.
Roth M, Chen W . Sorting out functions of sirtuins in cancer. Oncogene. 2013; 33(13):1609-20. PMC: 4295628. DOI: 10.1038/onc.2013.120. View

3.
Semenza G . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012; 33(4):207-14. PMC: 3437546. DOI: 10.1016/j.tips.2012.01.005. View

4.
Kai A, Chan L, Lo R, Lee J, Chak-Lui Wong C, Wong J . Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology. 2016; 64(2):473-87. PMC: 5074303. DOI: 10.1002/hep.28577. View

5.
Potter M, Newport E, Morten K . The Warburg effect: 80 years on. Biochem Soc Trans. 2016; 44(5):1499-1505. PMC: 5095922. DOI: 10.1042/BST20160094. View